SHELTON, Conn., Sept. 11, 2017 /PRNewswire/
-- NanoViricides, Inc., (NYSE "NNVC") today announced it will
be featured as a presenting company at the 19th Annual
Rodman & Renshaw Global Investment Conference, sponsored by
H.C. Wainwright & Co.,
LLC. The conference is being held on September 10-12, 2017 at Lotte New York Palace
Hotel in New York City.
Eugene Seymour, MD MPH, CEO of
NanoViricides, Inc., will provide an overview of the Company's
business during the live presentation and will be available to
participate in one-on-one meetings with investors who are
registered to attend the conference.
If you are an institutional investor, and would like to attend
the Company's presentation, please click on the following link
(www.rodmanevents.com) to register for the Rodman & Renshaw
conference. Once your registration is confirmed, you will be
prompted to log into the conference website to request a one-on-one
meeting with the Company.
Event: 19th Annual Rodman & Renshaw Global
Investment Conference
Presentation Date: September
12, 2017
Presentation Time: 12:05PM EDT
Location: Adams; Lotte New
York Palace Hotel in New York
City
About NanoViricides, Inc
NanoViricides, Inc. (www.nanoviricides.com) is a development
stage company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including H1N1 swine flu, H5N1
bird flu, seasonal Influenza, HIV, shingles, oral and genital
Herpes, viral diseases of the eye including EKC and herpes
keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus,
among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
that are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission.. Although it is not possible to
predict or identify all such factors, they may include the
following: demonstration and proof of principle in pre-clinical
trials that a nanoviricide is safe and effective; successful
development of our product candidates; our ability to seek and
obtain regulatory approvals, including with respect to the
indications we are seeking; the successful commercialization of our
product candidates; and market acceptance of our products.
View original content with
multimedia:http://www.prnewswire.com/news-releases/nanoviricides-inc-announces-its-ceo-dr-seymour-to-present-at-the-19th-annual-rodman--renshaw-global-investment-conference-in-new-york-city-on-september-12-2017-300516981.html
SOURCE NanoViricides, Inc.